Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183


Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients.

Clark C, Shah S, Herman-Ferdinandez L, Ekshyyan O, Abreo F, Rong X, McLarty J, Lurie A, Milligan EJ, Nathan CO.

Laryngoscope. 2010 Jun;120(6):1159-65. doi: 10.1002/lary.20917.


Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.

Nathan CO, Amirghahari N, Abreo F, Rong X, Caldito G, Jones ML, Zhou H, Smith M, Kimberly D, Glass J.

Clin Cancer Res. 2004 Sep 1;10(17):5820-7.


Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01.

Amornphimoltham P, Sriuranpong V, Patel V, Benavides F, Conti CJ, Sauk J, Sausville EA, Molinolo AA, Gutkind JS.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4029-37.


Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.

Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, Gutkind JS.

Cancer Res. 2005 Nov 1;65(21):9953-61.


Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer.

Johnson SM, Gulhati P, Rampy BA, Han Y, Rychahou PG, Doan HQ, Weiss HL, Evers BM.

J Am Coll Surg. 2010 May;210(5):767-76, 776-8. doi: 10.1016/j.jamcollsurg.2009.12.008.


Transgenic mice expressing constitutively active Akt in oral epithelium validate KLFA as a potential biomarker of head and neck squamous cell carcinoma.

Moral M, Segrelles C, Martínez-Cruz AB, Lorz C, Santos M, García-Escudero R, Lu J, Buitrago A, Costa C, Saiz C, Ariza JM, Dueñas M, Rodriguez-Peralto JL, Martinez-Tello FJ, Rodriguez-Pinilla M, Sanchez-Cespedes M, Digiovanni J, Paramio JM.

In Vivo. 2009 Sep-Oct;23(5):653-60.


Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative.

Molinolo AA, Hewitt SM, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses García A, Raimondi AR, Jufe R, Itoiz M, Gao Y, Saranath D, Kaleebi GS, Yoo GH, Leak L, Myers EM, Shintani S, Wong D, Massey HD, Yeudall WA, Lonardo F, Ensley J, Gutkind JS.

Clin Cancer Res. 2007 Sep 1;13(17):4964-73.


Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma.

Freudlsperger C, Horn D, Weißfuß S, Weichert W, Weber KJ, Saure D, Sharma S, Dyckhoff G, Grabe N, Plinkert P, Hoffmann J, Freier K, Hess J.

Int J Cancer. 2015 Jun 15;136(12):2775-85. doi: 10.1002/ijc.29328. Epub 2014 Nov 26.


Identification of a Novel Proto-oncogenic Network in Head and Neck Squamous Cell Carcinoma.

Georgy SR, Cangkrama M, Srivastava S, Partridge D, Auden A, Dworkin S, McLean CA, Jane SM, Darido C.

J Natl Cancer Inst. 2015 Jun 10;107(9). pii: djv152. doi: 10.1093/jnci/djv152. Print 2015 Sep.


Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.

Yamada Y, Kohashi K, Fushimi F, Takahashi Y, Setsu N, Endo M, Yamamoto H, Tokunaga S, Iwamoto Y, Oda Y.

Cancer. 2014 Mar 15;120(6):864-76. doi: 10.1002/cncr.28506. Epub 2013 Dec 18.


Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.

Horn D, Hess J, Freier K, Hoffmann J, Freudlsperger C.

Expert Opin Ther Targets. 2015 Jun;19(6):795-805. doi: 10.1517/14728222.2015.1012157. Epub 2015 Feb 5. Review.


The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies.

Vander Broek R, Mohan S, Eytan DF, Chen Z, Van Waes C.

Oral Dis. 2015 Oct;21(7):815-25. doi: 10.1111/odi.12206. Epub 2013 Dec 23. Review.


Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro.

Lin CL, Chiang WF, Tung CL, Hsieh JL, Hsiao JR, Huang WT, Feng LY, Chang CH, Liu SY, Tsao CJ, Feng YH.

Mol Med Rep. 2015 Jan;11(1):547-54. doi: 10.3892/mmr.2014.2700. Epub 2014 Oct 20.


Increased NBS1 expression is a marker of aggressive head and neck cancer and overexpression of NBS1 contributes to transformation.

Yang MH, Chiang WC, Chou TY, Chang SY, Chen PM, Teng SC, Wu KJ.

Clin Cancer Res. 2006 Jan 15;12(2):507-15.


Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.

Sun ZJ, Zhang L, Hall B, Bian Y, Gutkind JS, Kulkarni AB.

Clin Cancer Res. 2012 Oct 1;18(19):5304-13. doi: 10.1158/1078-0432.CCR-12-1371. Epub 2012 Aug 2.


The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck.

Mandal M, Younes M, Swan EA, Jasser SA, Doan D, Yigitbasi O, McMurphey A, Ludwick J, El-Naggar AK, Bucana C, Mills GB, Myers JN.

Oral Oncol. 2006 Apr;42(4):430-9. Epub 2006 Jan 27.


Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy.

Sepiashvili L, Hui A, Ignatchenko V, Shi W, Su S, Xu W, Huang SH, O'Sullivan B, Waldron J, Irish JC, Perez-Ordonez B, Liu FF, Kislinger T.

Mol Cell Proteomics. 2012 Nov;11(11):1404-15. doi: 10.1074/mcp.M112.020933. Epub 2012 Aug 23.


A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.

Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, Diao L, Fan YH, Stemke-Hale K, Heymach JV, Myers JN, Glisson BS, Johnson FM.

Mol Cancer Ther. 2014 Nov;13(11):2738-50. doi: 10.1158/1535-7163.MCT-13-1090. Epub 2014 Sep 5.

Supplemental Content

Support Center